


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: March 20, 2002

Signature: 
(Michael H. Teschner)

0400
0430
#33/26/02
Docket No.: EGYPT 3.9-021 CONT
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Cusgenot *et al.*

Application No.: 10/081,348

Group Art Unit:

Filed: February 22, 2002

Examiner: Not Yet Assigned

For: PROSTATIC CELL LINE AND USE
THEREOF TO OBTAIN AN ESTABLISHED
PROSTATIC CANCER IN AN ANIMAL

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT


Dear Sir:


It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. Some of the cited references were listed on the search report issued in connection with applicants' corresponding PCT application. A copy of each reference and a copy of the PCT search report are enclosed. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: March 20, 2002

Respectfully submitted,

By 
Michael H. Teschner
Registration No.: 32,862
LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, New Jersey 07090
(908) 654-5000
Attorneys for Applicant



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/081,348
				Filing Date	February 22, 2002
				First Named Inventor	Oliver Cussenot
				Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	EGYP 3.9-021 CONT


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	A	-WO 98/05797-	02-12-1988	Calydon		
	B	-WO 98/16628-	04-23-1998	The Regents of the University of California		
	C	-WO 97/35616-	10-02-1997	Pacific Northwest Cancer Foundation		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/081,348		
		Filing Date	February 22, 2002		
		First Named Inventor	Oliver Cussenot		
		Group Art Unit			
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	EGYP 3.9-021 CONT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	D	Sato et al., Metastatic and androgen-sensitive human prostate cancer animal model using orthotopic inoculation of LNCaP cells in SCID mice, 155 J. Urology, No. 5 Suppl. (1996)	✓
	E	Cussenot et al., 214 Experimental Cell Research, 83-92 (1994)	✓
	F	Eaton et al., Growth of a spontaneous canine prostatic adenocarcinoma in vivo and in vitro: isolation and characterization of neoplastic prostatic epithelial cell line CPA 1, 12 The Prostate, No. 2, 129-143 (1988)	✓
	G	Anz et al., Surgical Orthotopic Implantation Allows High Lung and Lymph Node Metastatic Expression of Human Prostate Carcinoma Cell Line PC-3 in Nude Mice, 34 Prostate No. 3, 169-174 (1988)	✓
	H	Van Weerden et al., Development of seven new human prostate tumor xenograft models and their histopathological characterization, 149 Am. J. Pathology, No. 3, (September 1996)	✓
	I	Israeli et al., Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen, 53 Cancer Research, No. 2 227-230 (1993)	✓
	J	J.W. Aquila et al., 36 The Prostate, 189-93 (1998)	✓
	K	Anidjar Maurice et al., In vivo model mimicking natural history of dog prostate cancer, 46 Prostate No. 1, 2-10 (2001)	✓
	L	Navone et al., Model Systems of Prostate Cancer: Uses and Limitations, 17 Cancer Metastasis No. 4, 361-71 (1999)	✓
	M	Horoszewicz et al., 7 Anticancer Research, 927-36 (1987)	✓
	N	Wright et al., 1 Urological Oncology, 18-28 (1995)	✓
	O	Horoszewicz et al., 43 Cancer Research, 1809-18 (1983)	✓
	P	Stone et al., 21 Int'l J. of Cancer, 274-81 (1978)	✓
	Q	Kaighn et al., 17 Investigations in Urology, 16-23 (1979)	✓
	R	"Gene Delivery Systems" OECD Documents, 2 rue Andre-Pascal 75775 Paris Cedex 16 France (1996)	✓
	S	Harlow et al. Antibodies: A Laboratory Manual, Cold Spring Harbor NY 346-355 (1988)	✓
	T	Voller et al., Bull. World health Organ., 53, 55 (1976)	✓
	U	Avrameas et al., 8 Scand. J. Immunol. No. 7 Suppl. 7 (1978)	✓
	V	Wilson et al., Immunofluorescence and related staining techniques, Elsevier/North Holland Biomedical Press, Amsterdam 215 (1978)	✓
	W	Hijmans et al., 4 Clin. Exp. Immunol. 457 (1969)	✓
	X	Goding et al., 13 J. Immunol. Meth., 215 (1976)	✓

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.